Standard Bank's net profit jumps 243pc in Q1
IBN SINA Pharma's EPS surges 17pc in Q3
FE Report | Tuesday, 12 May 2020
The net profit of Standard Bank surged 243 per cent year-on-year to nearly Tk 365 million in the first quarter (Q1) for January-March, 2020 despite ongoing Covid-19 pandemic.
The board of directors of the bank in a virtual meeting through digital platform recently approved among others, the un-audited financial statements of the bank for the first quarter ended on March 31, 2020 and disclosed it.
As per the disclosure, the bank's net profit after tax stood at Tk 364.95 million in January-March, 2020 which was Tk 106.25 million in the same period of the previous year.
The bank's consolidated earnings per share (EPS) also rose more than 245 per cent in January-March, 2020 quarter compared to the same quarter of the previous year.
Its consolidated EPS stood at Tk 0.38 for January-March 2020 as against Tk 0.11 for January-March 2019.
The consolidated net asset value (NAV) per share stood at Tk 17.38 as on March 31, 2020 which was Tk 15.55 in the same period last year.
The bank's consolidated net operating cash flow per share (NOCFPS) was Tk 5.65 in the negative for January-March 2020 as against Tk 3.96 for January-March 2019.
Each share of the bank, which was listed on the Dhaka Stock Exchange in 2003, closed at Tk 8.80 on March 25, the last trading day before the lockdown started.
Its share traded between Tk 7.30 and Tk 11.50 in the last one year.
The board of directors of the bank has recently recommended 5.0 per cent cash and 5.0 per cent stock dividend for the year ended on December 31, 2019.
The bank declared 5.0 per cent cash dividend which is worth Tk 479 million.
The bank's paid-up capital is Tk 9.58 billion and authorised capital is Tk 15 billion, while the total number of securities is 958.08 million.
The sponsor-directors own 39.63 per cent stake in bank, while the institutional investors own 21.96 per cent, foreign investors 1.26 per cent and the general public 37.15 per cent as on February 29, 2020, the DSE data showed.
The IBN SINA Pharma: The IBN SINA Pharmaceutical Industry's earnings per share rose more than 17 per cent year-on-year in third quarter (Q3) for January-March, 2020 amid ongoing Covid-19 pandemic.
The board of directors of the company in a virtual meeting recently approved the third quarter (Q3) un-audited financial statements of the company for the period from January 01 to March 31, 2020.
The board has also disclosed the nine months earnings per share, net asset value per share and net operating cash flow per share as per regulations of 16 (2) of the Dhaka and Chittagong Stock Exchange listing regulations-2015.
As per the official disclosure, the company's EPS stood at Tk 2.33 in Q3 for January-March, 2020 quarter which was Tk 1.99 in the same period last year.
In nine months, the company's EPS was Tk 9.63 for July 01, 2019 to March 31, 2020 as against Tk 7.95 for July 1, 2018 to March 31, 2019.
Its net operating cash flow per share was Tk 9.54 for July 01, 2019 to March 31, 2020 as against Tk 12.60 for the same period in the previous year.
The net asset value per share stood at Tk 53.94 as on March 31, 2020.
Each share of the company, which was listed on the Dhaka Stock Exchange in 1989, closed at Tk 220.20 on March 25, the last trading day before the government general holiday started.
Its share traded between Tk 192 and Tk 290.90 in the last one year.
The board of directors of the company disbursed 30 per cent cash dividend for the year ended on June 30, 2019.
The company's paid-up capital is Tk 312.44 million and authorised capital is Tk 500 million, while the total number of securities is 31.24 million.
The sponsor-directors own 44.44 per cent stake in company, while the institutional investors own 21.72 per cent and the general public 33.84 per cent as on February 29, 2020, the DSE data showed.